Impact of Dysbiosis on Intestinal Health in Young Adults with Chronic Inflammatory Diseases
DOI:
https://doi.org/10.56294/shp2025216Keywords:
gut microbiota, dysbiosis, chronic inflammatory diseases, young adults, probioticsAbstract
Introduction: Gut microbiota played an essential role in human health, especially in functions such as digestion, vitamin synthesis and immune regulation. When this microbial balance was altered, dysbiosis emerged, a condition associated with chronic inflammatory diseases (CID) such as ulcerative colitis and Crohn's disease. In Argentina, these pathologies significantly affected young adults, influenced by factors such as industrialized diets and the excessive use of antibiotics. This study analyzed the relationship between intestinal microbiota and CID in this vulnerable population.
Development: The investigation revealed that patients with CID presented a lower bacterial diversity and an increase in proinflammatory species, such as adherent-invasive *Escherichia coli*. Environmental factors such as a diet low in fiber and rich in saturated fats, as well as the early use of antibiotics, contributed to these microbial alterations. In addition, dysbiosis was found to be associated with increased inflammatory biomarkers and greater clinical severity. Genetic influences on the predisposition to develop dysbiosis were also identified. The study considered emerging treatments, such as the use of probiotics, prebiotics and fecal microbiota transplantation, which offered promising but still preliminary results.
Conclusions: It was concluded that intestinal dysbiosis played a determinant role in the development and progression of CID in young adults. The need to implement public health policies that promote healthy eating habits and control the use of antibiotics was highlighted, as well as the need to promote new research on therapeutic interventions based on the microbiota.
References
Li X, Wang E, Tian H, Yang H, Gao Y, Chen Y, et al. Causal relationship between gut microbiota and autoimmune diseases: a two-sample Mendelian randomization study. Front Immunol. 2022;13:851407. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35140703/
Sebastián-Domingo JJ, Sánchez-Sánchez C. De la flora intestinal al microbioma. Rev Esp Enferm Dig. 2018;110(1):51-9. Disponible en: https://scielo.isciii.es/scielo.php?pid=S1130-01082018000100009&script=sci_arttext
Ng SC, Bernstein CN, Vatn MH, et al. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol. 2008;5(12):706-13. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18515412/
Adolph TE, Tilg H. Western diets and chronic diseases. Nat Med. 2024;30(8):2133-47.
Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. The gut microbiota in inflammatory bowel disease. Nat Microbiol. 2022;7(3):280-94. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35273921/
Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol. 2015;50(8):942-51.
Becattini S, Taur Y, Pamer EG. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10:572912. Disponible en: https://www.frontiersin.org/articles/10.3389/fcimb.2020.572912/full
Baigrie D, Tilgner J, Heuschen P, et al. High ulcerative colitis and Crohn’s disease ratio in a population-based registry from Córdoba, Argentina. World J Gastroenterol. 2021;27(4):312-20. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33531211/
Martin HM, Campbell BJ, Hart CA, et al. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev. 2018;31(1):e00060-18. Disponible en: https://journals.asm.org/doi/full/10.1128/cmr.00060-18
Lopez-Siles M, Enrich-Capo N, Aldeguer X, Sabat-Mir M, Duncan SH, Garcia-Gil LJ. Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease. Appl Environ Microbiol. 2015;81(21):7582-92. Disponible en: https://journals.asm.org/doi/full/10.1128/aem.02006-15
Lee RM, Smith PB, Cohen RD. Continued statural growth in older adolescents and young adults with Crohn’s disease and ulcerative colitis beyond the time of expected growth plate closure. Inflamm Bowel Dis. 2020;26(12):1880-5. Disponible en: https://academic.oup.com/ibdjournal/article/26/12/1880/5714217
Burisch J, Jess T. Environmental and genetic factors in the pathogenesis of inflammatory bowel disease. Gastroenterol Rev. 2018;32(2):151-62. Disponible en: https://journals.viamedica.pl
Lopez-Siles M, Duncan SH, Garcia-Gil LJ, Martinez-Medina M. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2020;33(1):e00123-19. Disponible en: https://cmr.asm.org
Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiota alterations in inflammatory bowel disease. J Crohns Colitis. 2020;14(8):1253-63. Disponible en: https://academic.oup.com
Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Clin Microbiol Rev. 2018;31(4):e00060-18. Disponible en: https://journals.asm.org
Wang T, Cai G, Qiu Y, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2020;14:1027-38.
Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol. 2019;9:2.
Zuo T, Ng SC. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018;9:2247.
Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015.
Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56-64.
Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-4.
Published
Issue
Section
License
Copyright (c) 2025 Emanuel Zenon Aviza Joaquín, Daniel Nestor Chiacchiara (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
